Finland· FI-REL-REL58535

Sogroya

A somapacitan product containing somapacitan, registered in Finland by Novo Nordisk A/S. The same ATC class is registered in 13 of our 19 countries.

ATC H01AC07

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedSogroyaATCH01AC07REGISTER NO.FI-REL-REL58535PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Somapacitan is registered in 13 of 19 countries.

Countries holding a registration under ATC H01AC07 (somapacitan), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 8 of them publish a price we can compare per daily dose

Somapacitan · ATC H01AC07

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Somapacitan
Manufacturer
Novo Nordisk A/S
Country
Finland (FI)
ATC code
H01AC07
ATC class
Somapacitan
Defined daily dose
0.6 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

303 interactions on record for somapacitan.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Somapacitan · interactions on record

303 records

  • 2 severe
  • 296 moderate
  • 5 minor

Most severe, free to view

  • OmeprazoleA02BC01moderate
  • PantoprazoleA02BC02moderate
  • LansoprazoleA02BC03moderate
  • RabeprazoleA02BC04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Somapacitan in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All somapacitan products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Sogroya
  • Norway · Sogroya

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e0a90583-a716-41f4-9fd5-b8d31564940e
GET /v1/drugs/e0a90583-a716-41f4-9fd5-b8d31564940e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektioneste, liuos, esitäytetty kynä",
  "route": "Ihon alle",
  "ddd_unit": null,
  "strength": "5 mg/1.5 ml",
  "atc_label": "somapasitaani",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/20/1501/003-004",
  "fimea_rel_id": "REL58535",
  "authorised_at": "2022-04-25"
}

See everything about somapacitan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.